RecruitingEarly Phase 1NCT06485661

Effect of Captopril on GLS in Duchenne Myodystrophy

Intermediate Term Effect of Captopril on Left Ventricle Global Longitudinal Strain in Patients With Duchenne Myodystrophy


Sponsor

Ain Shams University

Enrollment

20 participants

Start Date

Jan 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

To outline the intermediate term effect of prescribing Captopril as an add on therapy on Left ventricular functions as measured by Global longitudinal strain in patients with Duchenne myodystrophy (DMD)


Eligibility

Sex: MALEMin Age: 6 Years

Inclusion Criteria1

  • Genetically confirmed Duchenne myodystrophy (DMD) patients with abnormal GLS < -18% with minimum age of 6 years old.

Exclusion Criteria3

  • Any patient who refuses to sign an informed consent.
  • Contraindication to ACEI: hypersensitivity - renal impairment - bilateral renal artery stenosis - aortic valve stenosis - hyperkalemia - hypotension.
  • Reduced ejection fraction below 50%.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCaptopril Tablets

Patients will be given captopril to see effect on global longitudinal strain


Locations(1)

Ain Shams university

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06485661


Related Trials